Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Efrem Cox

Neurological Surgery Las Vegas, NV Medical Doctor

NPI 1841581527 CMS profile 1394823

8530 W Sunset Rd Ste 250, Las Vegas, NV 89113

Open in the dashboard

General payments

$44,702

433 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Efrem Cox of Las Vegas, NV is reported in the CMS Open Payments database as having received $44,702 across 433 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,376 92
2024 General $4,556 83
2023 General $3,567 43
2022 General $17,957 58
2021 General $9,709 96
2020 General $4,852 52
2019 General $1,686 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Efrem Cox
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Efrem Cox were reported at $2,376. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Efrem Cox Neurological Surgery median Middle half National median
2019 $1,686 $582 $138–$3,006 $163
2020 $4,852 $294 $76–$2,174 $114
2021 $9,709 $387 $105–$2,432 $132
2022 $17,957 $542 $139–$2,989 $149
2023 $3,567 $534 $145–$2,697 $160
2024 $4,556 $574 $155–$3,046 $164
2025 $2,376 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $25,128 43 payments
  2. DePuy Synthes Sales Inc. $6,043 285 payments
  3. Globus Medical, Inc. $3,202 10 payments
  4. Providence Medical Technology, Inc. $2,588 34 payments
  5. Medical Device Business Services, Inc. $2,436 8 payments
  6. NuVasive, Inc. $895 7 payments
  7. Spineology Inc. $629 2 payments
  8. Pacira Pharmaceuticals Incorporated $589 5 payments
  9. icotec Medical Inc. $485 4 payments
  10. KLS-Martin L.P. $393 3 payments
  11. Other $2,313 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $23,300 7 payments
  2. Food and Beverage $16,638 409 payments
  3. Travel and Lodging $4,532 15 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $232 2 payments
Products named General payments · program years 2019–2025
  1. NIAGARA LATERAL ACCESS SYSTEM $9,000 3 payments
  2. CASCADIA INTERBODY SYSTEM $6,769 3 payments
  3. XIA 3 $6,000 1 payment
  4. ES2 SPINAL SYSTEM $6,000 1 payment
  5. RAVINE LATERAL ACCESS SYSTEM $6,000 1 payment
  6. TRITANIUM $6,000 1 payment
  7. EVEREST SPINAL SYSTEM $4,291 9 payments
  8. VIPER $2,753 135 payments
  9. Excelsius Robotics System $1,479 2 payments
  10. Teligen $1,351 55 payments
  11. Other $16,026 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

579

Median for Neurosurgery: 83

Drug cost

$3,418

Median for Neurosurgery: $872

Branded share of claims

2.1%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 140 $1,220
Methocarbamol Generic 124 $1,200
Meloxicam Generic 268 $584
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $152
Pregabalin Generic 13 $125
Cyclobenzaprine Hcl Generic 11 $90
Tizanidine Hcl Generic 11 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$61,435

Medicare's payments for the services billed

Medicare patients

226

Average age 75

Services billed

351

122 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 39%
Diabetes 37%
Atrial fibrillation 29%
Depression 29%
Chronic kidney disease 28%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

433 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record